Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein

Cardiovascular disease is the leading worldwide cause of death. Apolipoprotein E (ApoE) is a 34-kDa circulating glycoprotein, secreted by the liver and macrophages with pleiotropic antiatherogenic functions and hence a candidate to treat hypercholesterolaemia and atherosclerosis. Here, we describe a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ioannis Papaioannou, J. Paul Simons, James S. Owen
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/148796
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554405646303232
author Ioannis Papaioannou
J. Paul Simons
James S. Owen
author_facet Ioannis Papaioannou
J. Paul Simons
James S. Owen
author_sort Ioannis Papaioannou
collection DOAJ
description Cardiovascular disease is the leading worldwide cause of death. Apolipoprotein E (ApoE) is a 34-kDa circulating glycoprotein, secreted by the liver and macrophages with pleiotropic antiatherogenic functions and hence a candidate to treat hypercholesterolaemia and atherosclerosis. Here, we describe atheroprotective properties of ApoE, though also potential proatherogenic actions, and the prevalence of dysfunctional isoforms, outline conventional gene transfer strategies, and then focus on gene correction therapeutics that can repair defective APOE alleles. In particular, we discuss the possibility and potential benefit of applying in combination two technical advances to repair aberrant APOE genes: (i) an engineered endonuclease to introduce a double-strand break (DSB) in exon 4, which contains the common, but dysfunctional, ε2 and ε4 alleles; (ii) an efficient and selectable template for homologous recombination (HR) repair, namely, an adeno-associated viral (AAV) vector, which harbours wild-type APOE sequence. This technology is applicable ex vivo, for example to target haematopoietic or induced pluripotent stem cells, and also for in vivo hepatic gene targeting. It is to be hoped that such emerging technology will eventually translate to patient therapy to reduce CVD risk.
format Article
id doaj-art-11323930837b4986b3e3ca5bdac8b27d
institution Kabale University
issn 2090-8016
2090-0597
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-11323930837b4986b3e3ca5bdac8b27d2025-02-03T05:51:36ZengWileyCardiology Research and Practice2090-80162090-05972012-01-01201210.1155/2012/148796148796Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 ProteinIoannis Papaioannou0J. Paul Simons1James S. Owen2Division of Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UKDivision of Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UKDivision of Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UKCardiovascular disease is the leading worldwide cause of death. Apolipoprotein E (ApoE) is a 34-kDa circulating glycoprotein, secreted by the liver and macrophages with pleiotropic antiatherogenic functions and hence a candidate to treat hypercholesterolaemia and atherosclerosis. Here, we describe atheroprotective properties of ApoE, though also potential proatherogenic actions, and the prevalence of dysfunctional isoforms, outline conventional gene transfer strategies, and then focus on gene correction therapeutics that can repair defective APOE alleles. In particular, we discuss the possibility and potential benefit of applying in combination two technical advances to repair aberrant APOE genes: (i) an engineered endonuclease to introduce a double-strand break (DSB) in exon 4, which contains the common, but dysfunctional, ε2 and ε4 alleles; (ii) an efficient and selectable template for homologous recombination (HR) repair, namely, an adeno-associated viral (AAV) vector, which harbours wild-type APOE sequence. This technology is applicable ex vivo, for example to target haematopoietic or induced pluripotent stem cells, and also for in vivo hepatic gene targeting. It is to be hoped that such emerging technology will eventually translate to patient therapy to reduce CVD risk.http://dx.doi.org/10.1155/2012/148796
spellingShingle Ioannis Papaioannou
J. Paul Simons
James S. Owen
Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
Cardiology Research and Practice
title Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
title_full Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
title_fullStr Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
title_full_unstemmed Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
title_short Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
title_sort targeted in situ gene correction of dysfunctional apoe alleles to produce atheroprotective plasma apoe3 protein
url http://dx.doi.org/10.1155/2012/148796
work_keys_str_mv AT ioannispapaioannou targetedinsitugenecorrectionofdysfunctionalapoeallelestoproduceatheroprotectiveplasmaapoe3protein
AT jpaulsimons targetedinsitugenecorrectionofdysfunctionalapoeallelestoproduceatheroprotectiveplasmaapoe3protein
AT jamessowen targetedinsitugenecorrectionofdysfunctionalapoeallelestoproduceatheroprotectiveplasmaapoe3protein